Shunbin Xiong, Ph.D.
Department of Genetics, Division of Discovery Science
About Dr. Shunbin Xiong
Shunbin Xiong was born in southeast region of China, and received his bachelor degree in Biochemistry at Fudan University in Shanghai. He completed his Ph.D. at the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. After he finished his postdoctoral training in Baylor College of Medicine, he moved to The University of Texas, M.D. Anderson Cancer Center in 1999. He is currently an Assistant Professor in the Department of Genetics.
Dr. Xiong’s research focus is to investigate p53 pathway using genetically modified mouse models. Tumor suppressor gene p53 is often mutated or inhibited by its negative regulators, Mdm2 and Mdm4, in human cancers. Dr. Xiong has discovered Mdm2 and Mdm4 cooperatively inhibit p53 activity during the development of the central nervous system, and Mdm2 and Mdm4 suppress p53 activity in embryonic development and adult stage, respectively. Furthermore, he shows overexpression of Mdm4 induces tumorigenesis and has a p53-independent function in mice. Dr. Xiong also demonstrates that Mdm4 overexpression cooperates with an oncogenic K-ras mutation to drive lung tumorigenesis in vivo. Dr. Xiong is also working on mutant p53 gain of function (GOF) in tumorigenesis and cancer metastasis. His work indicates phospholipase Pla2g16 mediates mutant p53 GOF in osteosarcoma metastasis. Dr. Xiong has also discovered different p53 mutations driving mammary tumorigenesis with distinct GOF ability. His research goal is to understand p53 pathway in vivo and identify therapeutic targets in cancer treatment.
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Genetics, Division of Discovery Science, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1995 | Shanghai Institute of Biochemistry, Chinese Academy Of Sciences, Shanghai, CN, Biochemistry, Ph.D |
| 1990 | Fudan University, Shanghai, CN, Biochemistry, BS |
Postgraduate Training
| 1996-1999 | Postdoc Associate, Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas |
| 1995-1996 | Postdoc Associate, Department of Cell Biology, Baylor College of Medicine, Houston, Texas |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2022
Instructor, Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2003 - 2007
Research Associate, Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2001 - 2003
Research Associate, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999 - 2001
Editorial Activities
Associate Editor, Frontier in Genetics, 2020 - Present
Associate Editor, Frontier in Oncology, 2020 - Present
Professional Memberships
Selected Presentations & Talks
National Presentations
- 2018. To investigate mutant p53 gain of function with a conditional p53R245W allele. Poster. 9th International MDM2 workshop. St. Pete, FL, US.
- 2018. Mutant p53 Gain-of-Function in osteosarcoma metastasis. Invited. Sarcoma Alliance for Research through Collaboration (SARC) annual meeting. chicago, IL, US.
- 2015. Gain of Function Activities of p53R245W in a Conditional Knock-in Mouse Model. Conference. AACR Tumor metastasis. Austin, TX, US.
- 2013. The Pla2g16 Phospholipase Mediates Gain-of-Function Activities of Mutant p53. Poster. Maui, HI, US.
- 2011. Mining for Genes Involved in Metastasis in p53+/515A (p53R172H/+)Mice. Poster. Orlando, FL, US.
- 2010. Spontaneous tumorigenesis in mice overexpressing Mdm4. Conference. AACR/JCA 8th Joint Conference: Cancer Genomics, Epigenomics, and the Development of Novel Therapeutics. Waikoloa, HI, US.
- 2009. Overexpression of Mdm4 Induced Spontaneous Tumorigenesis in Mice. Conference. Mechanisms & Models of Cancer, Salk Institute for Biological Studies. La Jolla, CA, US.
- 2009. Overexpression of Mdm4 Induced Spontaneous Tumorigenesis in Mice. Conference. La Jolla, CA, US.
- 2007. Overexpression of Mdm4 induces spontaneous tumorgenesis in vivo. Poster. AACR annual meeting. Los Angeles, CA, US.
- 2006. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Poster. p53 workshop. New York, NY, US.
- 2005. Cooperative Inactivation of p53 by Mdm2 and Mdm4 in Central Nervous System. Poster. Keystone, CO, US.
- 2005. Cooperative Inactivation of p53 by Mdm2 and Mdm4 in Central Nervous System Development. Conference. Cellular Senescence and Cell Death. Keystone, CO, US.
International Presentations
- 2023. The amino terminus of Mdm4 contributes to p53 inhibition in vivo. Invited. The 10th international MDM2 workshop. Tokyo, JP.
- 2023. Differential gain-of-function activity of three p53 hotspot mutants in vivo. Poster. Lisbon, PT.
- 2019. To investigate mutant p53 gain of function with a conditional p53R245W allele. Conference. 8th Mutant p53 workshop. Lyon, FR.
- 2017. To investigate mutant p53 gain of function with a conditional p53R245W allele. Conference. The 17th International p53 Workshop. Biopolis, SG.
- 2016. The p53 Inhibitor Mdm4 Cooperates with Multiple Genetic Lesions in Tumorigenesis. Conference. 7th International Mutant p53 Wrokshop. Melbourne, AU.
- 2014. The Pla2g16 Phospholipase Mediates Gain-of-Function Activities of Mutant p53. Conference. 16th p53 international workshop. Stockholm, SE.
- 2013. The Pla2g16 Phospholipase Mediates Gain-of-Function Activities of Mutant p53. Conference. The 3rd Guangzhou international symposium on oncology. Guangzhou, CN.
- 2011. Mining for Genes Involved in Metastasis in p53+/515A (p53R172H/+) Mice. Conference. 5th Mutant p53 Workshop” From bench to bedside across moue models”. Palazzo Chigi, Ariccia(Rome), IT.
- 2008. Overexpression of Mdm4 induces spontaneous tumorgenesis in vivo. Conference. 14th International p53 workshop. Shanghai, CN.
Formal Peers
- 2018. Mutant p53 Gain-of-Function in osteosarcoma metastasis. Invited. Chicago, IL, US.
Grant & Contract Support
| Date: | 2022 - 2027 |
| Title: | A Pathway of Tumor Suppression |
| Funding Source: | NIH |
| Role: | Key |
| ID: | R01 47296 |
| Date: | 2018 - 2023 |
| Title: | Identifying vulnerabilities in p53 mutant tumors |
| Funding Source: | Brockman Foundation |
| Role: | Key Personnel |
| ID: | FP00006055 |
| Date: | 2015 - 2017 |
| Title: | Gain of function activities of p53R245W in a conditional knock-in mouse model |
| Funding Source: | U.T. MD Anderson Institute Research Grant |
| Role: | PI |
| ID: | IRG |
| Date: | 2008 - 2010 |
| Title: | The Role of Mdmx overexpression in Lymphoma/Myeloma Genesis and Therapy |
| Funding Source: | U.T. MD Anderson Cancer Center The Center for Targeted Therapy Disease-Specific Grant Program |
| Role: | PI |
| Date: | 2005 - 2007 |
| Title: | The role of Mdm4 in Tumorigenesis |
| Funding Source: | U.T. MD Anderson Cancer Center Institute Research Grant |
| Role: | PI |
| ID: | IRG |
| Date: | 1999 - 2025 |
| Title: | Role of p53 Missense Mutations on Tumorigenesis in Vivo |
| Funding Source: | NIH/NCI |
| Role: | Key Personnel |
| ID: | R01 CA082577 |
| Date: | 1988 - 2021 |
| Title: | A Pathway of Tumor Suppression |
| Funding Source: | NIH/NCI |
| Role: | Key Personnel |
| ID: | 1R01 CA047296 |
Selected Publications
Peer-Reviewed Articles
- Liu, B, Xiong, S, Williams-Villalobo, AE, Chau, GP, Qi, Y, Chen, H, Johnson, C, Chachad, D, McDaniel, JM, Su, X, El-Naggar, AK, Lozano, G, Zhang, Y. Stromal fibroblastic mutant Trp53 promotes mammary tumor development via enhanced secretion of paracrine factors. npj Breast Cancer 12(1), 2026. e-Pub 2026. PMID: 41387465.
- Xiong, S, Zhang, Y, Zhou, X, Pant, V, Mirani, A, Gencel-Augusto, J, Chau, GP, You, MJ, Lozano, G. Dependence on Mdm2 for Mdm4 inhibition of p53 activity. Cancer Letters 621, 2025. e-Pub 2025. PMID: 40081463.
- Puzio-Kuter, A, Xu, L, McBrayer, MK, Dominique, R, Li, HH, Fahr, BJ, Brown, AM, Wiebesiek, AE, Russo, BM, Mulligan, CL, Yang, H, Battaglia, J, Robell, KA, Thomas, DH, Huang, KS, Solovyov, A, Greenbaum, B, Oliner, JD, Davis, TW, Dumble, M, Johnson, M, Xiong, S, Yang, P, Lozano, G, Fellous, M, Vu, BT, Schram, AM, Levine, AJ, Poyurovsky, MV. Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator. Cancer discovery 15(6):1159-1179, 2025. e-Pub 2025. PMID: 39945593.
- McDaniel JM, Morrissey RL, Dibra D, Patel LR, Xiong S, Zhang Y, Chau GP, Su X, Qi Y, El-Naggar AK, Lozano G. p53R172H and p53R245W Hotspot Mutations Drive Distinct Transcriptomes in Mouse Mammary Tumors Through a Convergent Transcriptional Mediator. Cancer Res Commun 4(8):1991-2007, 2024. e-Pub 2024. PMID: 38994678.
- Dibra, D, Xiong, S, Moyer, SM, El-Naggar, AK, Qi, Y, Su, X, Kong, EK, Korkut, A, Lozano, G. Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo. Science Advances 10(7), 2024. e-Pub 2024. PMID: 38354236.
- Gencel-Augusto, J, Su, X, Qi, Y, Whitley, EM, Pant, V, Xiong, S, Shah, VV, Lin, J, Perez, E, Fiorotto, M, Mahmud, I, Jain, A, Lorenzi, PL, Navin, N, Richie, ER, Lozano, G. Dimeric p53 Mutant Elicits Unique Tumor-Suppressive Activities through an Altered Metabolic Program. Cancer discovery 13(5):1230-1249, 2023. e-Pub 2023. PMID: 37067911.
- Zhang, Y, Williams-Villalobo, AE, Godavarthi, JD, Shakoor, F, Xiong, S, Liu, B. Integrative bioinformatic analysis of p53 and pathway alterations in two different lung cancer subtypes. Biochemistry and Biophysics Reports 33, 2023. e-Pub 2023. PMID: 36532876.
- Yu X, Zhang Y, Xiong S, McDaniel JM, Sun C, Chau GP, Gencel-Augusto J, Chachad D, Morrissey RL, Rao X, Wang J, Lozano G. Omics analyses of a somatic Trp53R245W/+ breast cancer model identify cooperating driver events activating PI3K/AKT/mTOR signaling. Proc Natl Acad Sci U S A 119(45):e2210618119, 2022. e-Pub 2022. PMID: 36322759.
- Xiong S, Chachad D, Zhang Y, Gencel-Augusto J, Sirito M, Pant V, Yang P, Sun C, Chau G, Qi Y, Su X, Whitley EM, El-Naggar AK, Lozano G. Differential gain-of-function activity of three p53 hotspot mutants in vivo. Cancer Res 82(10):1926-1936, 2022. e-Pub 2022. PMID: 35320355.
- Pant V, Aryal NK, Xiong S, Chau GP, Fowlkes NW, Lozano G. Alterations of the MDM2 C-terminus differentially impact its function in vivo. Cancer Res 82(7):1313-1320, 2022. e-Pub 2022. PMID: 35078816.
- Zhang Y, Li Y, Chachad D, Liu B, Godavarthi JD, Williams-Villalobo A, Lasisi L, Xiong S, Matin A. In silico analysis of DND1 and its co-expressed genes in human cancers. Biochem Biophys Rep 29:101206, 2022. e-Pub 2022. PMID: 35059511.
- Kim MP, Li X, Deng J, Zhang Y, Dai B, Allton KL, Hughes TG, Siangco C, Augustine JJ, Kang Y, McDaniel JM, Xiong S, Koay EJ, McAllister F, Bristow CA, Heffernan TP, Maitra A, Liu B, Barton MC, Wasylishen AR, Fleming JB, Lozano G. Oncogenic KRAS recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis. Cancer Discov 11(8):2094-2111, 2021. e-Pub 2021. PMID: 33839689.
- Zhou X, Beilter A, Xu Z, Gao R, Xiong S, Paulucci-Holthauzen A, Lozano G, de Crombrugghe B, Gorlick R. Wnt/ß-catenin-mediated p53 suppression is indispensable for osteogenesis of mesenchymal progenitor cells. Cell Death Dis 12(6):521, 2021. e-Pub 2021. PMID: 34021120.
- Ueda K, Kumari R, Schwenger E, Wheat JC, Bohorquez O, Narayanagari SR, Taylor SJ, Carvajal LA, Pradhan K, Bartholdy B, Todorova TI, Goto H, Sun D, Chen J, Shan J, Song Y, Montagna C, Xiong S, Lozano G, Pellagatti A, Boultwood J, Verma A, Steidl U. MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. Cancer Cell 39(4):529-547.e7, 2021. e-Pub 2021. PMID: 33667384.
- Pant V, Xiong S, Wasylishen AR, Larsson CA, Aryal NK, Chau G, Tailor RC, Lozano G. Transient enhancement of p53 activity protects from radiation-induced gastrointestinal toxicity. Proc Natl Acad Sci U S A 116(35):17429-17437, 2019. e-Pub 2019. PMID: 31409715.
- Zhang Y, Xiong S, Liu B, Pant V, Celii F, Chau G, Elizondo-Fraire AC, Yang P, You MJ, El-Naggar AK, Navin NE, Lozano G. Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases. Nat Commun 9(1):3953, 2018. e-Pub 2018. PMID: 30262850.
- Ortiz GJ, Li Y, Post SM, Pant V, Xiong S, Larsson CA, El-Naggar AK, Johnson DG, Lozano G. Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes. Oncogene 37(3):332-340, 2018. e-Pub 2018. PMID: 28925402.
- Zhang Y, Hu Q, Li G, Li L, Liang S, Zhang Y, Liu J, Fan Z, Li L, Zhou B, Ruan Y, Yang X, Chen S, Mu T, Wang G, Xiong S. ONZIN Upregulation by Mutant p53 Contributes to Osteosarcoma Metastasis Through the CXCL5-MAPK Signaling Pathway. Cell Physiol Biochem 48(3):1099-1111, 2018. e-Pub 2018. PMID: 30041188.
- Pourebrahim R, Zhang Y, Liu B, Gao R, Xiong S, Lin PP, McArthur MJ, Ostrowski MC, Lozano G. Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein. Genes Dev 31(18):1847-1857, 2017. e-Pub 2017. PMID: 29021240.
- Pant V, Larsson CA, Aryal N, Xiong S, You MJ, Quintas-Cardama A, Lozano G. Tumorigenesis promotes Mdm4-S overexpression. Oncotarget 8(16):25837-25847, 2017. e-Pub 2017. PMID: 28460439.
- Yang X, Zhang Z, Jia X, Zhang Y, Mu T, Zhou B, Li L, Fu D, Hu X, Xiong S. High expression of PLA2G16 is associated with a better prognosis in HER2-positive breast cancer. J Thorac Dis 9(4):1002-1011, 2017. e-Pub 2017. PMID: 28523155.
- Xiong S, Pant V, Zhang Y, Aryal NK, You MJ, Kusewitt D, Lozano G. The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis. J Pathol 241(4):501-510, 2017. e-Pub 2017. PMID: 27925213.
- Gao Y, Xiao X, Zhang C, Yu W, Guo W, Zhang Z, Li Z, Feng X, Hao J, Zhang K, Xiao B, Chen M, Huang W, Xiong S, Wu X, Deng W. Melatonin synergizes the chemotherapeutic effect of 5-fluorouracil in colon cancer by suppressing PI3K/AKT and NF-κB/iNOS signaling pathways. J Pineal Res 62(2), 2017. e-Pub 2017. PMID: 27865009.
- Pant V, Xiong S, Chau G, Tsai K, Shetty G, Lozano G. Distinct downstream targets manifest p53-dependent pathologies in mice. Oncogene 35(44):5713-5721, 2016. e-Pub 2016. PMID: 27065327.
- Li L, Liang S, Wasylishen AR, Zhang Y, Yang X, Zhou B, Shan L, Han X, Mu T, Wang G, Xiong S. PLA2G16 promotes osteosarcoma metastasis and drug resistance via the MAPK pathway. Oncotarget 7(14):18021-35, 2016. e-Pub 2016. PMID: 26933804.
- Tashakori M, Zhang Y, Xiong S, You MJ, Lozano G. p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis. Mol Cancer Res 14(1):56-65, 2016. e-Pub 2016. PMID: 26527653.
- Mancini F, Pieroni L, Monteleone V, Lucà R, Fici L, Luca E, Urbani A, Xiong S, Soddu S, Masetti R, Lozano G, Pontecorvi A, Moretti F. MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response. Oncogene 35(2):228-40, 2016. e-Pub 2016. PMID: 25961923.
- Ren Z, Liang S, Yang J, Han X, Shan L, Wang B, Mu T, Zhang Y, Yang X, Xiong S, Wang G. Coexpression of CXCR4 and MMP9 predicts lung metastasis and poor prognosis in resected osteosarcoma. Tumour Biol 37(4):5089-96. e-Pub 2015. PMID: 26546437.
- Liang S, Ren Z, Han X, Yang J, Shan L, Li L, Wang B, Zhang Q, Mu T, Chen K, Xiong S, Wang G. PLA2G16 Expression in Human Osteosarcoma Is Associated with Pulmonary Metastasis and Poor Prognosis. PLoS One 10(5):e0127236, 2015. e-Pub 2015. PMID: 25993412.
- Quintás-Cardama A, Post S, Solis L, Xiong S, Yang P, Chen N, Wistuba I, Killary A, and Lozano G. The novel tumor suppressor and polarity gene TRIM62 (DEAR1) synergizes with oncogenic RAS in invasive lung cancer. Journal of Pathology 234(1):108-119, 2014. e-Pub 2014.
- Zhang Y, Xiong S, Li Q, Hu S, Tashakori M, Van Pelt C, You MJ, Pageon L, Lozano G. Tissue-specific and age-dependent effects of global Mdm2 loss. J Pathol 233(4):380-91, 2014. e-Pub 2014. PMID: 24789767.
- Xiong S, Tu H, Kollareddy M, Pant V, Li Q, Zhang Y, Jackson JG, Suh YA, Elizondo-Fraire AC, Yang P, Chau G, Tashakori M, Wasylishen AR, Ju Z, Solomon H, Rotter V, Liu B, El-Naggar AK, Donehower LA, Martinez LA, Lozano G. Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. Proc Natl Acad Sci U S A 111(30):11145-50, 2014. e-Pub 2014. PMID: 25024203.
- Xiong S, Mu T, Wang G, Jiang X. Mitochondria-mediated apoptosis in mammals. Protein Cell 5(10):737-49. e-Pub 2014. PMID: 25073422.
- Li Q, Zhang Y, El-Naggar AK, Xiong S, Yang P, Jackson JG, Chau G, Lozano G. Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors. Mol Cancer Res 12(6):901-11, 2014. e-Pub 2014. PMID: 24598047.
- Pant V, Xiong S, Jackson JG, Post SM, Abbas HA, Quintás-Cardama A, Hamir AN, Lozano G. The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity. Genes Dev 27(17):1857-67, 2013. e-Pub 2013. PMID: 23973961.
- McEvoy J, Flores-Otero J, Zhang J, Nemeth K, Brennan R, Bradley C, Krafcik F, Rodriguez-Galindo C, Wilson M, Xiong S, Lozano G, Sage J, Fu L, Louhibi L, Trimarchi J, Pani A, Smeyne R, Johnson D, Dyer MA. Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell 20(2):260-275, 2011. e-Pub 2011. PMID: 21840489.
- Pant V, Xiong S, Iwakuma T, Quintás-Cardama A, Lozano G. Mdm2-Mdm4 heterodimerization is critical for. Proc Natl Acad Sci U S A 108(29):11995-2000, 2011. e-Pub 2011. PMID: 21730132.
- Wang Y, Suh YA, Fuller MY, Jackson JG, Xiong S, Terzian T, Quintás-Cardama A, Bankson JA, El-Naggar AK, Lozano G. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest 121(3):893-904, 2011. e-Pub 2011. PMID: 21285512.
- Xiong S, Pant V, Suh YA, Van Pelt CS, Wang Y, Valentin-Vega YA, Post SM, Lozano G. Spontaneous Tumorigenesis in Mice Overexpressing the p53-Negative Regulator Mdm4. Cancer Res 70(18):7148-54, 2010. e-Pub 2010. PMID: 20736370.
- Lin PP, Pandey MK, Jin F, Xiong S, Deavers M, Parant JM, Lozano G. EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Res 68(21):8968-75, 2008. e-Pub 2008. PMID: 18974141.
- Liu G, Terzian T, Xiong S, Van Pelt CS, Audiffred A, Box NF, Lozano G. The p53-Mdm2 network in progenitor cell expansion during mouse postnatal development. J Pathol 213(4):360-8, 2007. e-Pub 2007. PMID: 17893884.
- Xiong S, Van Pelt CS, Elizondo-Fraire AC, Fernandez-Garcia B, Lozano G. Loss of Mdm4 Results in p53-Dependent Dilated Cardiomyopathy. Circulation 115(23):2925-2930, 2007. e-Pub 2007. PMID: 17533180.
- Xiong S, Van Pelt CS, Elizondo-Fraire AC, Liu G, Lozano G. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A 103(9):3226-31, 2006. e-Pub 2006. PMID: 16492743.
- Grier JD, Xiong S, Elizondo-Fraire AC, Parant JM, Lozano G. Tissue specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol 26(1):192-198, 2006. e-Pub 2006. PMID: 16354690.
- Yao J, Xiong S, Klos K, Nguyen N, Grijalva R, Li P, Yu D. Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene 20(56):8066-74, 2001. e-Pub 2001. PMID: 11781819.
- Xiong S, Grijalva R, Zhang L, Nguyen NT, Pisters PW, Pollock RE, Yu D. Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-beta1-activated p38 signaling pathway enhances endothelial cell migration. Cancer Res 61(4):1727-32, 2001. e-Pub 2001. PMID: 11245489.
- Zhang L, Yu D, Hu M, Xiong S, Lang A, Ellis LM, Pollock RE. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res 60(13):3655-61, 2000. e-Pub 2000. PMID: 10910082.
- Xiong S, Chirala SS, Wakil SJ. Sterol regulation of human fatty acid synthase promoter I requires nuclear factor-Y and Sp-1 binding sites. Proc Natl Acad Sci U S A 97(8):3948-3953, 2000. e-Pub 2000. PMID: 10759542.
- Xiong S, Chirala SS, Hsu MH, Wakil SJ. Identification of thyroid hormone response elements in the human fatty acid synthase promoter. Proc Natl Acad Sci U S A 95(21):12260-5, 1998. e-Pub 1998. PMID: 9770474.
Invited Articles
- Xiong S. Mouse models of Mdm2 and Mdm4 and their clinical implications. Chin J Cancer 32(7):371-5, 2013. e-Pub 2013. PMID: 23327795.
- Xiong S, Parker-Thornburg J, Lozano G. Developing genetically engineered mouse models to study tumor suppression. Curr Protoc Mouse Biol 2(1):9-24, 2012. e-Pub 2012. PMID: 22582146.
Review Articles
- Xiong Y, Zhang Y, Xiong S, Williams-Villalobo AE. A Glance of p53 Functions in Brain Development, Neural Stem Cells, and Brain Cancer. Biology (Basel) 9(9), 2020. e-Pub 2020. PMID: 32932978.
Patient Reviews
CV information above last modified March 06, 2026